Posters/Publications

poster

FASN Inhibitor Denifanstat Achieved All Endpoints in the Treatment of Acne Vulgaris: Results from a Phase III Randomised Placebo-Controlled Trial

2025 Fall Clinical Dermatology Conference

Date - 10/2025

oral

Highlighting Mechanism of Action of FASN Inhibitor Denifanstat in MASH

9th Annual MASH Drug Development Summit

Date - 09/2025

oral

Utilizing AI-Based Digital Pathology to Evaluate Denifanstat’s Anti-Fibrotic Effect in MASH Patients with Advanced Fibrosis

9th Annual MASH Drug Development Summit

Date - 09/2025

presentation

First-in-Class FASN Inhibitor Denifanstat Achieved All Endpoints in the Treatment of Acne Vulgaris: Results from a Phase 3 Randomised Placebo Controlled Trial

European Academy of Dermatology and Venereology (EADV) Congress 2025

Date - 09/2025

poster

Denifanstat improved multiple qFibrosis-based collagen features linked to major adverse liver outcomes in patients with metabolic dysfunction-associated steatohepatitis patients and high polygenic risk

EASL International Liver Congress

Date - 05/2025

poster

Assessment of metabolic dysfunction-associated steatohepatitis resolution index and component biomarkers in prediction of histology response to denifanstat in the FASCINATE-2 trial

EASL International Liver Congress

Date - 05/2025

poster

Denifanstat-mediated reduction of plasma glycine- and taurine-conjugated bile acids correlates with histological improvements in denifanstat-treated metabolic dysfunction-associated steatohepatitis patients in Phase 2b FASCINATE-2 study

EASL International Liver Congress

Date - 05/2025

oral

Denifanstat, a Fatty Acid Synthase Inhibitor, Increased Circulating Polyunsaturated Triglycerides and Decreased LDL-Cholesterol in MASH Patients with Advanced Fibrosis

Keystone Symposia

Date - 02/2025

poster

Denifanstat, a Fatty Acid Synthase Inhibitor, Increased Circulating Polyunsaturated Triglycerides and Decreased LDL-Cholesterol in MASH Patients with Advanced Fibrosis in a Post-Hoc Analysis of FASCINATE-2 Study

Keystone Symposia

Date - 02/2025

oral

FASN inhibitor

MASH TAG

Date - 01/2025